Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2018, specifically dated January 3, 2018. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the entry into a Collaborative Research Agreement with Hadassah Medical Center. This agreement aims to further explore the mechanism of action of the company's candidate drug, Namodenoson, in the context of Non-Alcoholic Steatohepatitis (NASH).
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section of the attached press release (Exhibit 99.1). No specific financial guidance, quantitative outlook, or detailed risk factors are enumerated within the body of this Form 6-K text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for details on the Hadassah Medical Center collaboration terms.
- Verify the specific scope of the Namodenoson mechanism of action study in NASH.
- Check subsequent filings for any financial impact or milestone payments related to this agreement.
- Confirm the status of the company's Registration Statements on Form F-3 referenced in the filing.